Verus' Childs' Play Brings in $98 Million A Round
This article was originally published in Start Up
Executive Summary
With a goal to focus on pediatric respiratory disease and allergy, several ex-Dura Pharmaceutical executives were able to attract $98 million in Series A funding without having technology, products, or IP. The company's June 2005 financing is another signal that investing in the highest-quality start-up biotechs is increasingly a game for VC firms with deep pockets.
You may also be interested in...
From Verus to Meritage: A Biotech Prototype for Tough Economic Times
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.
From Verus to Meritage: A Biotech Prototype for Tough Economic Times
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.
San Diego Still Shines Despite VC Setbacks
The San Diego life sciences industry has endured several losses or setbacks by local venture capital firms yet its start-ups remain top recipients of capital.